Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Gut microbiota research is advancing fast, but experts say microbiome-based therapies need to be personalized — not standardized. A new review finds promising signals for conditions like multiple sclerosis, dry eye, and food allergies, but highlights wide variability in evidence across strategies like probiotics, prebiotics, and fecal microbiota transplantation (FMT). The path forward? Biomarkers, multi-omics integration, and precision medicine.
Gut microbiota research is advancing fast, but experts say microbiome-based therapies need to be personalized — not standardized. A review published in the Journal of Investigational Allergology and Clinical Immunology finds that while dysbiosis (microbial imbalance) is consistently linked to inflammatory diseases, causality remains unproven. Conditions like multiple sclerosis, dry eye, and food allergies show promising responses to probiotics and other microbiota-targeted strategies, but evidence quality varies widely across interventions.
Researchers emphasize that early life is a critical window — disruptions like antibiotic use during pregnancy or infancy are linked to higher risks of asthma and atopic conditions. Interestingly, a COVID-era cohort study found that vertical mother-to-baby transmission matters more for allergy development than environmental microbial exposure.
Key Takeaways:
Why it matters: Microbiome therapies hold real promise for managing inflammatory diseases, but without validated biomarkers and personalized approaches, broad clinical recommendations remain premature. Precision medicine frameworks are the next frontier.